## KHC Office Hours Compass HQIC








2


#### **Presenters** Special guests: KDHE HAI/AR Program Michele Clark Eric Cook-Wiens Data & Measurement Director KHC Senior Director of Quality Initiatives & Special Projects Bryna Stacey, MPH, BSN, RN, CIC HAI/AR Program Director Bryna.Stacey@ks.gov Justin Blanding, MPH HAI/AR Senior Epidemiologist Kellie Wark, MD MPH Justin.blanding@ks.gov Asst. Prof Infectious Diseases, KUMC HAI/AS expert and AS Lead, KDHE Stephanie Lindemann, MPH kwark@kumc.edu AR Epidemiologist Erin McGuire 'morovement Advisor Kellie.wark@ks.gov Stephanie.Lindemann@ks.gov Heidi Courson Quality Impro KD COMPASS HOSPITAL QUALITY IMPROVEMENT CONTRACTOR Kansas Healthcare
























Kansas **Current State(s): ASP Core Elements Fulfilled** 7 Core Elements of a Hospital Antibiotic rdship Programs **Stewardship Program** Nationally, 91% of hospitals have met all 7 Core Elements (4,577 of 5,052). 1. Hospital Leadership Commitment 84% 2. Accountability 80% 80% 3. Pharmacy Expertise 77% 4. Action: Implement Interventions to 84% 72% Improve Antibiotic Use 90% 5. Tracking Antibiotic Use and Outcomes 6. Reporting Antibiotic Use and Outcomes 74% 96% 7. Education 82% 88% 84% 83% 72 - 84% CDC Resources: 89% 82% 85 - 90% Core Elements of Antibiotic Stewardship https://www.cdc.gov/antibiotic-use/core-92 - 94% elements/index.html 95 - 100% 85% Hospital Outpatient Nursing Homes \*More information on CDC's Core Elements of Hospital Antibiotic Stewardship Programs can be found at: Small and Critical Access Hospitals NTIBIOTICS Resource-limited Settings althcare Safety Network (NHSN) Annual Hospita

To protect and improve the health and environment of all Kansans













		AMR & Outcomes	·
Outcome	No. studies	% Reduction (IR, 95% CI range)	
Meta-analysis of 32 studies of ASF	s in 20 co		
MDR-Gram Negative Incid.	19	<b>51%</b> (0.49, 0.35-0.68)	Antibiotic Stewardship
CR-A.baumannii (CRAB)		<b>56%</b> (0.44, 0.17-1.13)	
CR-K.pneumoniae (CRE)		<b>48%</b> (0.52, 0.13-2.09)	
MRSA Infection & Colonization	17	<b>37%</b> (0.63, 0.45-0.88)	
C.diff infections	11	<b>32%</b> (0.68, 0.53-0.88)	<b>Infection</b> Prevention
Systematic review of 145 studies	1		
Mortality (guideline-adherence empiric tx)	19	<b>35%</b> (0.65, 0.54-0.80)	Antibiotic Stewardship Drevention Drevention Drevention Drevention
Mortality (de-escalation interventions)	19	56% (0.44, 0.30-0.66)	Environmental Services
Nephrotoxicity	13	<b>50%</b> (0.50, 0.29-0.80))	Baue D., et al. Lancet Infect Dis 2017;(17): 990-1001. Schuts E., et al. Lancet Infect Dis. 2016;16:857-56.








































Hospital Antibiotic Use				Infect	ion # cases	Antibiotic r	regimen most often	prescribed			
Last calendar year or last 12	months (all	ernatively, start	with one month	)		Antibiotic 1	Antibiotic 2	Antibiotic 3			
What are the 3 most common inf asymptomatic bacteriuria, acute ( patients are treated with antibioti	COPD exacert	ditions, (i.e., bation) for which	1. 2. 3.	Ex) UTI (cathete	r) Ex) 15/mg. (avg)	Route: IV Duration: 4 days Route: Route: Rou	piperacillin/tazobactam* Do Dose: 4.5 g (1/4 Rx were 3.375 g) Route: IV PC	Drug: levofloxacin Dose: 500 mg (2/3 Rx ware 750) * Route: IV (1/3 Rx PO)	Summary of facility antibiotics	Nun	nber
What proportion of asymptomati with an antibiotic	c bacteriuria	cases are treated		%		(average)) (aver IV to		Duration: 7 days (average, including IV to PO conversion)	Total number antibiotics reviewed		
What are the 3 most common an including asymptomatic bacteriu		ibed for UTIs	1	_		Drug: Dose: Route:	Drug: Dose: Route:	Drug: Dose: Route:	Total number of data sources reviewed (in addition to antibiotic orders)		
What proportion of acute broncl vith an antibiotic	Patient name/	Antibiotic (drug,	Indication for	Clinical notes	Micro/ imaging	Infection surveillanc	e Infection	Facility	Summary of facility antibiotic appropriateness	Number	%
What proportion of acute broncl	date	dose, duration)	antibiotic		results	log	surveillance criteria met		Antibiotic appropriate based on clinical documentation		
							_		Antibiotic appropriate for microbiologic data (and/or POC studies such as urinalysis, serologic, molecular studies,		
What are the 3 most common an pronchitis (regardless of whethe	ex) A, 1/1/20	ex) Cipro 250 mg p.o.		ex) Urine catheter in	ex) UA packed		ex) No	ex) No ex) No	or other lab data)		
What are the 3 most common an		BID x 14 days		place, cloudy	WBC, UC<10k				Antibiotic appropriate for imaging		
community acquired pneumor				urine	contamina nts				Antibiotic indication aligned with expectations outlined in facility policies/protocols (if applicable)		
What are the 3 most common an acquired pneumonia	ex) B, 1/2/20	ex) cefazolin		ex) erythema,	ex) n/a	ex) SSTI	ex) Yes	ex) Yes	Antibiotic indication aligned with CDC surveillance case definition		
What are the 3 most common an or infected wounds (and/or oth SSTIs))				fevers							
Other infections a concern in you											


## Kansas<br/>Facility Profile, Infection Profile


Last 12 months or last calendar year	Number	Last 12 months or last calendar year	Number		
Licensed beds		Clostridioides difficile			
Licensed beas		Facility onset infections			
Admissions		Community onset infections			
Patient days		Numbers of non-duplicate isolates of following isolates:			
and days		MDR Gram-Negative Bacteria			
Average daily census		Carbapenem-resistant Enterobacterales (E. coli, Klebsiella spp., Morganella, morganii., Proteus spp., Providencia spp.)			
Number of prescribers		Carbapenem-resistant Pseudomonas aeruginosa			
OP-1-1 - Laboration (have a second have		Carbapenem-resistant Acinetobacter baumannii			
Clinical pharmacists (hours per month)		ESBL Enterobacterales			
Patient characteristics	Average daily census	MDR Gram-Positive Bacteria	•		
Residents with indwelling urinary catheters		Methicillin-Resistant Staphylococcus aureus (MRSA)			
Residents with indivening unitary catheters		MRSA			
Residents with pressure injury o Stage 1-2		Vancomycin-Resistant Enterococci (VRE)	•		
o Stage 3-4 o Unstageable / unable to determine		VRE			
o Unstageable / unable to determine		Other drug-resistant gram-positives	•		
Patients admitted with acute on chronic foot or leg ulcers		Penicillin-Resistant Streptococcus pneumoniae (non-meningeal MIC)			
		Erythromycin-resistant group A Streptococcus			
		Clindamycin-resistant group B Streptococcus			
		Other MDROs of concern:			
Download Facility profile: https Infection Profile: https	://www.kdheks.gov/e ps://www.kdheks.gov	r pi/hai/CAH Toolkit/Table 12 Facility Profile /epi/hai/CAH Toolkit/Table 13 Facility Infec	docx tion Profile.docx		
To protec	ct and improve th	he health and environment of all Ka	nsans		
· · · ·	T				















	RX Name:			
X Patient Name:	DIAGNOSIS	Symptom duration	SYMPTOM RELIEF MEDICA	TIONS
DIAGNOSIS	Bronchitis (chest cold, cough)	7-21 days	Always use medications according to package instr Stop the medication when symptoms get bett	
Bronchitis (chest cold, cough): Add	ded19	3-21 days (+)	Acetaminophen, 325-650 mg every 4-6 hours as needed	fever and ach
Flu: 7 -14 days	Influenza (flu)	7-14 days	Ibuprofen, 400-800 mg every 4-6 hours as needed	fever and ach
Otitis media (middle ear infection): 7-10	Otitis media (ear infection)	7-10 days	Naproxen, 250-500 mg every 12 hours as needed	fever and ach
Upper respiratory infection (common cc 7-14 days	Upper respiratory infection (common cold)	7-10 days	Lozenges - benzocaine, dyclonine or zinc acetate	sore throat
Viral pharyngitis (sore throat): 3-10 days	<b>Viral pharyngitis</b> (sore throat)	3-10 days	□ Saltwater gargle -1 tbsp. salt /1 cup warm water	sore throat
Viral sinusitis (sinus infection): 7-14 days	<b>Viral sinusitis</b> (sinus infection)	7-14 days	Honey - 2 tbsp. /1 cup tea or hot water every 4-6 hours as nee (do not give honey to babies under 1 year)	ded sore throat, cough
The symptoms you presented with	The symptoms you presented with tode a VIRAL infection.		Nasal / sinus saline irrigation (i.e., neti pot, saline squeeze b 1-4 times daily as needed (do not use irrigations in kids under	ottle)
today suggest a VIRAL infection.	You have not been prescribed antibiotics because a <u>not</u> effective for viral infections, cause side effec- cause serious harm		Cool mist humidifier or vaporizer	chest & nasa congestion
You have not been prescribed antibiotics because antibiotics are <u>not</u> effective in	Please return or call if symptoms do not improve in you develop persistent fevers, shortness of breat		Dextromethorphan, 20-30 mg every 6 hours as needed (do use cough suppressants in kids under 4)	cough
treating viral infections, cause side effects, and may cause serious harm	symptoms:		If none of above working, you do NOT have heart problems or high blo Phenylephrine or pseudoephedrine, limit 2-3 days (do not use in kids under 4)	cough & congestio
THE UNIVERSITY OF KANSAS HEALTH SYSTEN	Kansas Healthcare-Associated   & Antimicrobial Resistance Advis		Prescriber: D	ate:




## Kansas Core Element 5-6: Tracking & Reporting

**Goal**: determine whether interventions impacted abx, reduced resistance


- Peer comparison (e.g. compare 1 high priority condition such as rate of abx for acute bronchitis)
- Monitor adverse events (C.diff rates)
- Pharmacist audits abx use
- Micro provides surveillance data (e.g., antibiogram, local resistant rates)
- Outcome monitoring (antibiotic resistance, mortality, morbidity)


To protect and improve the health and environment of all Kansans


41





42



















## KHC Office Hours Compass HQIC











































62












```
67
```



## Have Questions, Need Help?

#### **Kansas Healthcare Collaborative**

Heidi Courson **Quality Improvement Advisor** hcourson@khconline.org 785-231-1334

#### Erin McGuire

**Quality Improvement Advisor** emcguire@khconline.org 785-231-1333

#### **Michele Clark**

Senior Director of Quality Initiatives mclark@khconline.org 785-231-1321

#### **Eric Cook-Wiens**

Data and Measurement Director Ecook-wiens@khconline.org 785-231-1324

69



#### Kansas Hospital Association/QHi

#### Sally Othmer

Senior Director Data & Quality sothmer@kha-net.org 785-276-3118

#### **Stuart Moore**

Program Manager QHi smoore@kha-net.org 785-276-3104

#### **KHIN/KONZA**

Josh Mosier Manager of Client Services jmosier@khinonline.org 785-260-2761

#### **Rhonda Spellmeier**

**HIE Workflow Specialist** rspellmeier@khinonline.org 785-260-2795

COMPASS HOSPITAL QUALITY IMPROVEMENT CONTRACTOR





70





## TO THE PEOPLE OF KANSAS, GREETINGS:

WHEREAS, overuse and inappropriate use of antibiotics—in people, in pets, and in agricultural animals—leads to antibiotic resistance; and

WHEREAS, antibiotic resistance is an ongoing major threat to public health, creating limitations on available treatments for bacterial infections thus jeopardizing the ability of healthcare professionals to fight infectious disease; and

WHEREAS, antibiotic-resistance increases 4-fold or more when antibiotics are used inappropriately for viral infections such as COVID-19 giving this pandemic the potential to kill many more Kansans indirectly by driving antibiotic-resistant infections; and

WHEREAS, every year more than 2.8 million people in the United States contract antibiotic-resistant infections and more than 35,000 of those people die, and antibiotic-resistant infections are projected to kill 10 million people globally every year by 2050; and

WHEREAS, Kansas is the 8th highest antibiotic prescribing state with 904 antibiotic prescriptions per 1000 population, and in the bottom three states in the nation for implementing antibiotic stewardship programs in our healthcare facilities; and

WHEREAS, antibiotics are prescribed by a variety of health professionals to people, pets, and agricultural animals in Kansas, appropriate prescribing is truly a "One Health" mission and will require a collaborative effort; and

WHEREAS, raising awareness of this threat to public health and educating about appropriate antibiotic use promises to change attitudes and behaviors of healthcare professionals and the general public alike, leading to the proper prescribing and use of antibiotics—preserving their revolutionary ability to save lives for generations to come.

NOW, THEREFORE, I, Laura Kelly, GOVERNOR OF THE STATE OF KANSAS, do hereby proclaim November 18<sup>th</sup> through 24<sup>th</sup>, 2021 as

## Use Antibiotics Wisely Week

in the state of Kansas and I urge all citizens to join in this observation.



DONE: At the Capitol in Topeka under the Great Seal of the State this 18<sup>th</sup> day of November, A.D. 2021

BY THE GOVERNOR

Assistant Secretary of State

Secretary of State





## Overdose Data to Action (OD2A) Program

The Kansas Healthcare Collaborative (KHC) is working with the Kansas Department of Health and Environment (KDHE) on the Overdose Data to Action (OD2A) project. KHC is accepting applications from hospitals and/or clinics in high risk areas interested in participating in a quality improvement project related to preventing and/or decreasing harms associated with opioids and other controlled substances.

Focus areas may include:

- Decrease providers' self-reported opioid and/or other controlled substance prescribing rates;
- Increase the number of patients receiving non-pharmacological treatments;
- Decrease problematic co-prescribing (e.g. concurrent benzodiazepines and opioids); and
- Increase providers' access to Kansas's Prescription Drug Monitoring Program, K-TRACS.

### Project Timeline

Application Period:	Accepted on a first come basis, as funding is available.
Last Date to Start:	June 1, 2022
Wrap-Up Period:	August 31, 2022

#### Hospital and/or Clinic Responsibility

- 1) Assign a point of contact for the project and meet regularly with a KHC Quality Improvement Advisor in person or virtually during the project period.
- 2) Work with KHC to implement quality improvement cycles, change concepts, policy development and implementation around safe prescribing, screening processes, and/or increasing referrals to evidence-based treatment and other community-based resources, including the use of K-TRACS.
- 3) Agree to share details of the quality improvement project and create a storyboard with indiviulaized data for tracking progress (with the assistance of KHC staff) to be shared with KDHE and potentially other Kansas practices.

### **Benefits of Participation include:**

- Alignment with other KHC Quality Initiatives such as the HQIN and Compass HQIC initiatives' strategies for Behavioral Health, with a focus on Opioids and Patient Safety categories:
  - o Implement best practices for opioid and other controlled substance medication prescribing.
  - Decrease opioid-related adverse drug events for patients who take high-risk medications or have a behavioral health diagnosis.
- A small financial stipend upon completion of the project and submission of the storyboard.

For more information contact your KHC Quality Improvement Advisor or visit www.khconline.org/od2a

Kansas Healthcare Collaborative | OD2A Program Overview | Created 11/18/2021

## Engaging PFAC Members

December 16 1:00 - 2:00 PM (CST)

## **Overview**

Explore strategies for engaging PFAC members continuously throughout their term.

## Objectives

- + Explain the importance of each meeting in terms of providing information and soliciting input and solutions
- Review the key guidelines including the importance and appreciation of everyone's voice reflective of the diversity of the community
- Identify key areas of input needed by PFAC and plan meetings

## Register

https://us06web.zoom.us/j/89571534845?pwd=MktoeV FnaXIzSFVGb2t2MVU3cmViQT09 (Link)

# Upcoming PFAC Podcasts

Best approaches for PFAC recruitment + interviewing November 18

## Objectives

- + Explain the importance of each meeting in terms of providing information and soliciting input and solutions
- + Review the key guidelines including the importance and appreciation of everyone's voice reflective of the diversity of the community
- + Propose taking the PFAC members on a tour of the hospital along with explanation of units; may need to rotate tours to avoid any unit disruption
- Identify key areas of input needed by PFAC and plan meetings

## Tune In

https://www.ihconline.org/icompass/dashboard/post-list? category=hospital#page=0&subcategoryid=6837a60c-53e6-40f1ba1f-24c5865013e8&posttype=resource (Link)

## Review of Accomplishments January 2022

## Objectives

- Describe and review success stories on recruitment and valuable meetings
- Schedule and develop connections with PFAC members and staff

## Tune In

https://www.ihconline.org/icompass/dashboard/post-list? category=hospital#page=0&subcategoryid=6837a60c-53e6-40f1ba1f-24c3865013e8&posttype=resource (Link)

This material was prepared by Compass HQIC Network a Hospital Quality Improvement Contractor under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services (HHS). View expressed in this material do not necessarily reflect the official views or policy of CMS or HHS, and any reference to a specific product or entity herein does not constitute endorsement of that product or entity by CMS or HHS. 12SOW Compass HQIC Network/Hospital Quality Improvement Contractor – (0018) – 09/21/2021.

